Ocular changes after photodynamic therapy

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 1, 2006, Pages 377-385

  Tzekov, Radouil ^a   Lin, Ton ^a   Zhang, Kai Ming ^a   Jackson, Brittany ^a   Oyejide, Adelekan ^a   Orilla, Werhner ^a   Kulkarni, Amol D ^a,b   Kuppermann, Baruch D ^a,b   Wheeler, Larry ^a   Burke, James ^a  

^a ALLERGAN INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; DIAGNOSTIC AGENT; INDOCYANINE GREEN; PHOTOSENSITIZING AGENT; PORPHYRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOROID VASCULARIZATION; CONTROLLED STUDY; ELECTRORETINOGRAPHY; EYE FUNDUS; FEMALE; FLUORESCENCE ANGIOGRAPHY; HISTOPATHOLOGY; INDOCYANINE GREEN ANGIOGRAPHY; MONKEY; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; PRIMATE; PRIORITY JOURNAL; RETINA EDEMA; VISUAL SYSTEM; ANIMAL; CHEMICALLY INDUCED DISORDER; CHOROID; CHOROID DISEASE; DRUG EFFECT; FOLLOW UP; MACACA; PATHOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHOTOCHEMOTHERAPY; RETINA; RETINA MACULA CYSTOID EDEMA; VASCULARIZATION;

ANIMALS; ARTERIAL OCCLUSIVE DISEASES; CHOROID; CHOROID DISEASES; ELECTRORETINOGRAPHY; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; INDOCYANINE GREEN; MACACA FASCICULARIS; MACULAR EDEMA, CYSTOID; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RETINA; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 33644844662     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-0838     Document Type: Article

References (66)

1. Daniell MD, Hill JS. A history of photodynamic therapy. Aust N Z J Surg. 1991;61:340-348.
2. Wilson BC, Patterson MS. The physics of photodynamic therapy. Phys Med Biol. 1986;31:327-360.
3. Miller JW, Stinson WG, Gregory WA, el-Koumy HA, Puliafito CA. Phthalocyanine photodynamic therapy of experimental iris neovascularization. Ophthalmology. 1991;98:1711-1719.
4. Wilson CA, Saloupis P, Hatchell DL. Treatment of experimental preretinal neovascularization using photodynamic thrombosis. Invest Ophthalmol Vis Sci. 1991;32:2530-2535.
5. Lin SC, Lin CP, Feld JR, Duker JS, Puliafito CA. The photodynamic occlusion of choroidal vessels using benzoporphyrin derivative. Curr Eye Res. 1994;13:513-522.
6. Schmidt-Erfurth U, Hasan T, Gragoudas E, Michaud N, Flotte TJ, Birngruber R. Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology. 1994;101:1953-1961.
7. Kliman GH, Puliafito CA, Grossman GA, Gregory WA. Retinal and choroidal vessel closure using phthalocyanine photodynamic therapy. Lasers Surg Med. 1994;15:11-18.
8. Royster AJ, Nanda SK, Hatchell DL, Tiedeman JS, Dutton JJ, Hatchell MC. Photochemical initiation of thrombosis: fluorescein angiographic, histologic, and ultrastructural alterations in the choroid, retinal pigment epithelium, and retina. Arch Ophthalmol. 1988; 106:1608-1614.
9. Wachtlin J, Heimann H, Behme T, Foerster MH. Long-term results after photodynamic therapy with verteporfin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases. Graefes Arch Clin Exp Ophthalmol. 2003;241:899-906.
10. Ergun E, Heinzl H, Stur M. Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia. Am J Ophthalmol. 2004;138: 434-438.
11. Spaide RF, Martin ML, Slakter J, et al. Treatment of idiopathic subfoveal choroidal neovascular lesions using photodynamic therapy with verteporfin. Am J Ophthalmol. 2002;134:62-68.
12. Azab M, Benchaboune M, Blinder KJ, et al. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin in Photodynamic Therapy Study Report no. 4. Retina. 2004;24:1-12.
13. Paskowitz DM, Nune G, Yasumura D, et al. BDNF reduces the retinal toxicity of verteporfin photodynamic therapy. Invest Ophthalmol Vis Sci. 2004;45:4190-4196.
14. Zacks DN, Ezra E, Terada Y, et al. Verteporfin photodynamic therapy in the rat model of choroidal neovascularization: angiographic and histologic characterization. Invest Ophthalmol Vis Sci. 2002;43:2384-2391.
15. Peyman GA, Kazi AA, Unal M, et al. Problems with and pitfalls of photodynamic therapy. Ophthalmology. 2000;107:29-35.
16. Husain D, Miller JW, Michaud N, Connolly E, Flotte TJ, Gragoudas ES. Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization. Arch Ophthalmol. 1996;114:978-985.
17. Reinke MH, Canakis C, Husain D, et al. Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey. Ophthalmology. 1999;106:1915-1923.
18. Schlotzer-Schrehard U, Viestenz A, Naumann GO, Laqua H, Michels S, Schmidt-Erfurth U. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol. 2002;240:748-757.
19. Gaynes BI, Fiscella RG. Safety of verteporfin for treatment of subfoveal choroidal neovascular membranes associated with age-related macular degeneration. Expert Opin Drug Saf. 2004;3:345-361.
20. Tzekov RT, Gerth C, Werner JS. Senescence of human multifocal electroretinogram components: a localized approach. Graefes Arch Clin Exp Ophthalmol. 2004;242:549-560.
21. Moan J. Properties for optimal PDT sensitizers. J Photochem Photobiol B. 1990;5:521-524.
22. Kramer M, Miller JW, Michaud N, et al. Liposomal benzoporphyrin derivative verteporfin photodynamic therapy: selective treatment of choroidal neovascularization in monkeys. Ophthalmology. 1996;103:427-438.
23. Husain D, Kramer M, Kenny AG, et al. Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment. Invest Ophthalmol Vis Sci. 1999;40:2322-2331.
24. Schnurrbusch UE, Welt K, Horn LC, Wiedemann P, Wolf S. Histological findings of surgically excised choroidal neovascular membranes after photodynamic therapy. Br J Ophthalmol. 2001;85: 1086-1091.
25. Wachtlin J, Behme T, Heimann H, Kellner U, Foerster MH. Concentric retinal pigment epithelium atrophy after a single photodynamic therapy. Graefes Arch Clin Exp Ophthalmol. 2003;241: 518-521.
26. Shanmugam MP, Agarwal M. RPE atrophy following photodynamic therapy in type 2A idiopathic parafoveal telangiectasis. Indian J Ophthalmol. 2005;53:61-63.
27. Postelmans L, Pasteels B, Coquelet P, El Ouardighi H, Verougstraete C, Schmidt-Erfurth U. Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females. Am J Ophthalmol. 2004;138:803-808.
28. Bains HS, Cirino AC, Ticho BH, Jampol LM. Photodynamic therapy using verteporfin for a diffuse choroidal hemangioma in Sturge-Weber syndrome. Retina. 2004;24:152-155.
29. Farah ME, Costa RA, Muccioli C, Guia TA, Belfort R Jr. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 2002;134:137-139.
30. Schmidt-Erfurth UM, Michels S. Changes in confocal indocyanine green angiography through two years after photodynamic therapy with verteporfin. Ophthalmology. 2003;110:1306-1314.
31. Moshfeghi DM, Kaiser PK, Grossniklaus HE, et al. Clinicopathologic study after submacular removal of choroidal neovascular membranes treated with verteporfin ocular photodynamic therapy. Am J Ophthalmol. 2003;135:343-350.
32. Michels S, Schmidt-Erfurth U. Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci. 2003;44: 2147-2154.
33. Schlotzer-Schrehardt U, Viestenz A, Naumann GO, Laqua H, Michels S, Schmidt-Erfurth U. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol. 2002;240:748-757.
34. Tan W, Beaumont PE, Chang AA. Case series outcomes at 1 week following verteprofin photodynamic therapy. Retina. 2003;23: 166-170.
35. Schmidt-Erfurth U, Laqua H, Schlotzer-Schrehard U, Viestenz A, Naumann GO. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol. 2002;120:835-844.
36. Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci. 2002;43:830-841.
37. Ohnishi Y, Yoshitomi T, Murata T, Sakamoto T, Ishibashi T. Electron microscopic study of monkey retina after photodynamic treatment. Med Electron Microsc. 2002;35:46-52.
38. Rogers AH, Martidis A, Greenberg PB, Puliafito CA. Optical coherence tomography findings following photodynamic therapy of choroidal neovascularization. Am J Ophthalmol. 2002;134:566-576.
39. Montero JA, Ruiz-Moreno JM, Tavolato M. Follow-up of age-related macular degeneration patients treated by photodynamic therapy with optical coherence tomography 3. Graefes Arch Clin Exp Ophthalmol. 2003;241:797-802.
40. Mennel S, Hausmann N, Meyer CH, Horle S, Peter S. [Transient visual decrease after photodynamic therapy]. Ophthalmologe. 2005;102:58-63.
41. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2005; 112:301-304.
42. Tzekov R, Arden GB. The electroretinogram in diabetic retinopathy. Surv Ophthalmol. 1999;44:53-60.
43. Jiang L, Jin C, Wen F, Huang S, Wu D, Wu L. The changes of multifocal electroretinography in the early stage of photodynamic therapy for choroidal neovascularization. Doc Ophthalmol. 2003; 107:165-170.
44. Palmowski AM, Allgayer R, Heinemann-Vernaleken B, Ruprecht KW. Influence of photodynamic therapy in choroidal neovascularization on focal retinal function assessed with the multifocal electroretinogram and perimetry. Ophthalmology. 2002;109:1788-1792.
45. Moschos MN, Panayotidis D, Moschos MM, Bouros C, Theodossiadis PG, Theodossiadis GP. A preliminary assessment of macular function by MF-ERG in myopic eyes with CNV with complete response to photodynamic therapy. Eur J Ophthalmol. 2003;13: 461-467.
46. Moschos MM, Panayotidis D, Theodossiadis G, Moschos M. Assessment of macular function by multifocal electroretinogram in age-related macular degeneration before and after photodynamic therapy. J Fr Ophthalmol. 2004;27:1001-1006.
47. Lai TY, Chan WM, Lam DS. Transient reduction in retinal function revealed by multifocal electroretinogram after photodynamic therapy. Am J Ophthalmol. 2004;137:826-833.
48. Arnold JJ, Blinder KJ, Bressler NM, et al. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3. Am J Ophthalmol. 2004;137:683-696.
49. Meyer CH, Lapolice DJ, Fekrat S. Functional changes after photodynamic therapy with verteporfin. Am J Ophthalmol. 2005;139: 214-215.
50. Hee MR, Baumal CR, Puliafito CA, et al. Optical coherence tomography of age-related macular degeneration and choroidal neovascularization. Ophthalmology. 1996;103:1260-1270.
51. Ho AC, Yannuzzi LA, Guyer DR, Slakter JS, Sorenson JA, Orlock DA. Intraretinal leakage of indocyanine green dye. Ophthalmology. 1994;101:534-541.
52. Huang Y, Obana A, Gohto Y, Nakajima S. Comparative study of the phototoxicity of two chrolin type photosensitizers, ATX-S10(Na) and verteporfin, on vascular endothelial and retinal pigment epithelial cells. Lasers Surg Med. 2004;34:216-226.
53. Arias L, Pujol O, Berniell J, et al. Impact of lesion size on photodynamic therapy with verteporfin of predominantly classic lesions in age related macular degeneration. Br J Ophthalmol. 2005;89: 312-315.
54. Houle JM, Strong A. Clinical pharmacokinetics of verteporfin. J Clin Pharmacol. 2002;42:547-557.
55. Soubrane G, Bressler NM. Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: focus on clinical application of verteporfin photodynamic therapy. Br J Ophthalmol. 2001;85:483-495.
56. Haimovici R, Kramer M, Miller JW, et al. Localization of lipoprotein-delivered benzoporphyrin derivative in the rabbit eye. Curr Eye Res. 1997;16:83-90.
57. Sarna T. Properties and function of the ocular melanin - a photobiophysical view. J Photochem Photobiol B. 1992;12:215-258.
58. Kayatz P, Thumann G, Luther TT, et al. Oxidation causes melanin fluorescence. Invest Ophthalmol Vis Sci. 2001;42:241-246.
59. Boulton M, Rozanowska M, Rozanowski B. Retinal photodamage. J Photochem Photobiol B. 2001;64:144-161.
60. Moan J, Peng Q, Sorensen R, Iani V, Nesland JM. The biophysical foundations of photodynamic therapy. Endoscopy. 1998;30:387-391.
61. Grant WE, Speight PM, MacRobert AJ, Hopper C, Bown SG. Photodynamic therapy of normal rat arteries after photosensitisation using disulphonated aluminium phthalocyanine and 5-aminolaevulinic acid. Br J Cancer. 1994;70:72-78.
62. Hare WA, Ton H. Effects of APB, PDA, and TTX on ERG responses recorded using both multifocal and conventional methods in monkey: effects of APB, PDA, and TTX on monkey ERG responses. Doc Ophthalmol. 2002;105:189-222.
63. Neuenschwander S, Castelo-Branco M, Singer W. Synchronous oscillations in the cat retina. Vision Res. 1999;39:2485-2497.
64. Miller JW, Schmidt-Erfurth U, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol. 1999;117:1161-1173.
65. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Arch Ophthalmol. 1999;117:1329-1345.
66. Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol. 2001;119:198-207.